Syndromic Diagnostics of Respiratory Infections in Children As One of Antibiotic Management Tools in a Hospital

An observational, ambispective, non-interventional study was conducted to compare the effectiveness of introducing syndromic diagnostic according to the RP-2021 protocol on the basis of the pediatric departments of the Morozov Children's City Clinical Hospital. The study was carried out in two phases. The prospective phase (February–June 2022) was conducted using multiplex PCR tests (mPCR) – BioFire FilmArray respiratory panel – and routine diagnostic tests according to accepted standards for patient examination. The second phase of the study was a retrospective analysis of the comparison group’s (historical control group) primary medical records for standard test results from the same time frame, February to June 2021. Data on 40 patients on the historical control group were taken from the CIS EMIAS system.
The mPCR results of the prospective group were available to the doctor several hours later, at the very beginning of the diagnostic algorithm. The length of the hospital stay in the prospective period following the introduction of mPCR testing was reduced by one day compared to the period before the introduction of this technology.
The study showed that express methods of syndromic diagnostic testing allow to quickly establish the etiology of a respiratory infection for preterm infants, as well as children with bronchopulmonary dysplasia, bronchiolitis, comorbid patients, patients in the ICU with suspected influenza, whooping cough, and atypical pathogens, which in turn optimizes antibiotics prescription and hospitalization time. This study highlights the importance of rapid diagnosis of respiratory pathogens in pediatric patients under the age of five in order to optimize patient management when admitting them to the emergency department with a suspected acute respiratory infection.
In the prospective observation group after the introduction of mPCR testing, patients were significantly less likely to receive antibiotics — 47.5% (n=19) compared to the historical control group of 72.5% (n=29). The study presents the advantages of the syndromic approach to the diagnosis of respiratory infections in children as one of the most effective tools for increasing the rationality of antibiotic use in a children's hospital.

1. Lee BR, Hassan F, Jackson MA, Selvarangan R. Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections. J Clin Virol. 2019 Jan;110:11-16. doi: 10.1016/j.jcv.2018.11.006.

2. Meyer Sauteur PM, Unger WW, Nadal D, Berger C, Vink C, van Rossum AM. Infection with and Carriage of Mycoplasma pneumoniae in Children. Front Microbiol. 2016 Mar 23;7:329. doi: 10.3389/fmicb.2016.00329.

3. Li J, Tao Y, Tang M, Du B, Xia Y, Mo X, Cao Q. Rapid detection of respiratory organisms with the FilmArray respiratory panel in a large children's hospital in China. BMC Infect Dis. 2018 Oct 11;18(1):510. doi: 10.1186/s12879-018-3429-6.

4. Loens K, Ieven M. Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics. Front Microbiol. 2016 Mar 31;7:448. doi: 10.3389/fmicb.2016.00448.

5. Brendish NJ, Malachira AK, Armstrong L, Houghton R, Aitken S, Nyimbili E, Ewings S, Lillie PJ, Clark TW. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med. 2017 May;5(5):401-411. doi: 10.1016/S2213-2600(17)30120-0.

6. Kitano T, Nishikawa H, Suzuki R, Onaka M, Nishiyama A, Kitagawa D, Oka M, Masuo K, Yoshida S. The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan. J Infect Chemother. 2020 Jan;26(1):82-85.

7. Livingstone R, Lin H, Brendish NJ, Poole S, Tanner AR, Borca F, Smith T, Stammers M, Clark TW. Routine molecular point-of-care testing for SARS-CoV-2 reduces hospital-acquired COVID-19. J Infect. 2022 Apr;84(4):558-565. doi: 10.1016/j.jinf.2022.01.034. Epub 2022 Jan 31. PMID: 35108599; PMCID: PMC8802147.

8. Clark TW, Beard KR, Brendish NJ, Malachira AK, Mills S, Chan C, Poole S, Ewings S, Cortes N, Nyimbili E, Presland L. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021 Apr;9(4):419-429. doi: 10.1016/S2213-2600(20)30469-0.

9. Kitano T, Nishikawa H, Suzuki R, Onaka M, Nishiyama A, Kitagawa D, Oka M, Masuo K, Yoshida S. The impact analysis of a multiplex PCR respiratory panel for hospitalized pediatric respiratory infections in Japan. J Infect Chemother. 2020 Jan;26(1):82-85. doi: 10.1016/j.jiac.2019.07.014.